Human Vaccines Market Overview
The human vaccines market reached a valuation of USD 2.8 billion in 2015, it will reach a value of USD 5.46 billion and a CAGR of 11.8 % in the forecast period.
The emergence of infectious diseases is leading the biotech company to enhance the development of vaccines. The research and development activities for vaccines are driving the market. The support from the government for vaccine development and focus on immunization is another factor driving the market. The heavy capital investments by private and public organizations for low purchasing power in developing countries may restrain the market growth.
The travel rates have increased far greater distances, and people living in densely populated areas get closer contact with wild animals. Due to this, the rate of infectious diseases has increased. This has also led to global epidemics. For decades many infectious diseases such as avian flu, swine flu, Zika, SARS, MERS, Ebola, chikungunya, and most recently was, COVID-19 - SARS-CoV-2. This has led to the market’s developments. The concern for infectious diseases has increased in recent years, and the demand for vaccines is propelling. The growing emergence of new diseases enhances the research and development activities and funding initiatives, which will propel the market in the forecast period.
Study Objectives Middle East and Africa Human Vaccines Market:
Middle East and Africa Human Vaccines Market, by Technology, 2015 (%)
Key Players for Middle East and Africa Human Vaccines Market:
Some of the key players in this market are GlaxoSmithKline Plc., Merck & Co. Inc., Pfizer, Inc., Sanofi Pasteur, Inc., AstraZeneca Plc., Bharat Biotech, Shenzhen Kangtai Biological Products, Valeant Pharmaceuticals, Emergent Biosolutions Inc., Astellas Pharma Inc., Panacea Biotec and others.
In May 2022
Kenya Healthcare Federation, the Health Sector Board of Kenya Private Sector Alliance (KEPSA), has praised the government for securing the deal for the Moderna vaccine. This will lead to the set up of a USD 500 million manufacturing facility in Kenya. This will produce 500 million doses of mRNA vaccines each year.
In May 2022
Intravacc B.V. is a global leader in translational research and the development of preventive and therapeutic vaccines. The company has announced an agreement with Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd in China for Avacc 3, which is an OMV-based whooping cough vaccine.
According to the agreement, Zhifei Lvzhu will receive the license for the Chinese territory and Africa, South America, and Asian countries. Intravacc will receive benchmark and upfront payments over net sales. The companies will continue to collaborate to tailor the Avacc 3 concept vaccine in territories, including toxicology, upscaling, and clinical trials.
Middle East and Africa human vaccines market has been segmented on the basis of technology which comprises attenuated, inactivated, toxoid, conjugate & subunit, recombinant DNA. On the basis of disease indication; market is segmented into pneumococcal, influenza, hepatitis, rotavirus, DTP, polio and others. On the basis of type the market is segmented into prophylactic and therapeutic. On the basis of composition market is again segmented into mono vaccine and combination vaccines. The route of administration segments the market into oral, injectable and other. Moreover on the basis of end user; market is segmented into children and adults.
Regional Analysis of Middle East and Africa Human Vaccines Market:
Depending on geographic region, human vaccine market is segmented into several countries: UAE is the largest market for human vaccines in the entire Middle East and Africa human vaccines market closely followed by Egypt. The rest of Africa’s market especially Sub Saharan regions are however the fastest growing market with a huge unmet medical needs.
Middle East and Africa Human Vaccines Market is projected to grow at an 11.8% CAGR between 2014-2022.
Middle East and Africa Human Vaccines Market is predicted to touch USD 5.46 billion by 2022.
UAE is predicted to dominate the Middle East and Africa Human Vaccines Market.
Unmet vaccination needs and development of new vaccines are adding market growth.
Side effects may limit market growth.